GET THE APP

Most current and up to date treatment options for non-melanoma sk | 9467
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

Most current and up to date treatment options for non-melanoma skin cancers


14th International Conference on Clinical and Experimental Dermatology

June 19-20, 2017 Philadelphia, USA

Neil Sandhu

Daystar Skin and Cancer Center, USA

Keynote: J Clin Exp Dermatol Res

Abstract :

Nonmelanoma skin cancer (NMSC) is the most common type of cancer amongst the Caucasian population. Basal cell carcinoma and squamous cell carcinoma are the two types of non-melanoma skin cancers. These skin cancers require treatment with Mohs Surgery, excision, superficial radiotherapy, cryosurgery, Electrodessication and curettage, Blu-U light treatment Imiquimod, or 5-Flurouracil. Mohs surgery is the most effective treatment for all types of BCC and SCC greater than 2 cm in diameter. Mohs surgery cure rate is 97% for SCC and 99% for BCC. Standard excisions are performed on BCC and SCC less than 2 cm in diameter. The cure rate for a standard excision is 98% for BCC and 95% for SCC. Electrodissection and cautery is performed by using a sharp ring curette instrument to remove the epidermis and dermis that contains cancer cells. Then we use electrocautery to char the base of the wound. This is best used to treat low risk NMSC. Superficial radiotherapy is a noninvasive low energy radiotherapy that penetrates only a short distance below the surface of the skin. This is best for people who are not candidates for surgery. Cryotherapy involves using a device that sprays liquid nitrogen to freeze and then thaw the areas of concern causing a local cellular destruction. This is used for superficial BCC and in situ SCC. Imiquimoid and topical 5-Fluorouracil (5FU) are best used for superficial BCC but not for SCC. Lastly, the Blu-U light treatment is best used for actinic keratosis (AK), which is pre-cancerous. After application of Levulan Kerastick to the AKs, exposure to the Blu light causes a reaction to occur which destroys the AK cells.

Biography :

Neil Sandhu, MD, is a Board-Certified Dermatologist (ABD) and is the Medical Director for Daystar Skin and Cancer Center. He served as Chief Resident at UMDNJ-New Jersey Medical School. His training puts him at the cutting-edge in Cosmetic Dermatology and Skin Cancer Surgery. He is also trained in cosmetic procedures including BOTOX and filler injections, chemical peels, and photorejuvenation. He attended the University of Wisconsin, where he graduated Summa Cum Laude before going on to attend the University of Wisconsin School of Medicine & Public Health, where he again graduated as the top of his class. He has authored multiple scientific articles, including one focusing on the use of laser procedures in dermatology. He is a member of the American Society for Dermatologic Surgery and the American Society of Mohs Surgery.

Email: sandhu.neil@gmail.com

Top
https://www.olimpbase.org/1937/